85-1587-37 CD30, Recombinant, Human (TNFRSF8, Tumor Necrosis Factor Receptor Superfamily Member 8, CD30L Receptor, Ki-1 Antigen, Lymphocyte Activation Antigen CD30, D1S166E) 100ug C2382-15

※お見積書はカートで印刷できます

冷凍 保管・搬送時に冷凍が必要な商品です。

特徴

  • CD30, also known as Ki-1 antigen and , is a 120kD type I transmembrane glycoprotein belonging to the TNF receptor superfamily. Mature human CD30 consists of a 361aa extracellular domain with six cysteine-rich repeats, a 28aa transmembrane segment, and a 188aa cytoplasmic domain. In contrast, mouse and rat CD30 lack 90aa of the ECD and contain only three cysteine-rich repeats. Within common regions of the ECD, human CD30 shares 53% and 49% aa sequence identity with mouse and rat CD30, respectively. Alternate splicing of human CD30 generates an isoform that includes only the C-terminal 132aa of the cytoplasmic domain. CD30 is normally expressed on antigen-stimulated Th cells and B cells. However, it is up-regulated in Hodgkin's disease (on Reed-Sternberg cells), other lymphomas, chronic inflammation, and autoimmunity. CD30 binds to CD30 Ligand/ TNFSF8 which is expressed on activated Th cells, monocytes, granulocytes and medullary thymic epithelial cells. CD30 signaling co-stimulates antigen-induced Th0 and Th2 proliferation and cytokine secretion but favors a Th2-biased immune response. In the absence of antigenic stimulation, it can still induce T cell expression of IL-13. CD30 contributes to thymic negative selection by inducing the apoptotic cell death of CD4+CD8+ T cells. In B cells, CD30 ligation promotes cellular proliferation and antibody production in addition to the expression of CXCR4, CCL3, and CCL5. An 85-90kD soluble form of CD30 is shed from the cell surface by TACE-mediated cleavage. Soluble CD30 retains the ability to bind CD30 Ligand and functions as an inhibitor of normal CD30 signaling.
  • Source:Recombinant corresponding to aa1-369 from human TNFRSF8, expressed in mouse myeloma cell line, NS0.
  • Molecular Weight:~38.4kD
  • Biological Activity:Measured by its ability to block CD30 Ligand-induced IL-6 secretion by HDLM human Hodgkin’s lymphoma cells. The ED50 for this effect is typically 1-5ug/ml in the presence of 50ng/ml of Recombinant Human CD30 Ligand.
  • Endotoxin: ~1EU/1ug (LAL)
  • Storage and Stability:Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile buffer. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 6 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

仕様

  • Size:100ug
  • Source Antigen:Recombinant, NS0 cells
  • Grade:Highly Purified
  • Purity:~95% (SDS-PAGE)
  • Form:Supplied as a lyophilized powder in PBS. Reconstitute with PBS to 0.1mg/ml.
  • Molecular Weight Non Ab:38.4
  • Swiss Prot Number:P28908
  • EU Commodity Code:30021019
  • この商品は法規制を確認しておりません。(法規制によって販売できない場合もございます)
  • 製品の仕様は予告なく変更になる場合がございます。最新仕様はメーカーホームページをご確認ください。
  • 【試薬に関するお問合せ】
  • アズワン株式会社 試薬・プロセス材料グループ
  • TEL:06-6447-8641
  • FAX:06-6447-8642
  • E-mail:[email protected]
アズワン品番
85-1587-37
型番
C2382-15
入り数
1個
標準価格
282,000円(税抜)
WEB価格
アズワン在庫 [?]
数量

※お気に入り機能はログイン後にご利用いただけます

よくあるご質問

よくあるご質問(FAQ)

掲載カタログ情報

掲載カタログ名 掲載ページ

次の商品を登録しました。

商品計:

お買い物を続ける カートを見る